E-LIB Suche - Ergebnisse für: Daniel Bottomly

1

Just how transformative will AI/ML be for immuno-oncology?:

Bottomly, Daniel ; McWeeney, Shannon
Journal for ImmunoTherapy of Cancer. 12 (2024) 3 - p. e007841 , 2024

2

Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resis..:

Modak, Rucha V. ; de Oliveira Rebola, Katia G. ; McClatchy, John...
Clinical Cancer Research. 30 (2024) 10 - p. 2245-2259 , 2024

Link: https://doi.org/10.1158/..

3

Upregulation of HOXA3 by isoform‐specific Wilms tumour 1 dr..:

Allen, Basil ; Savoy, Lindsey ; Ryabinin, Peter...
British Journal of Haematology. 205 (2024) 1 - p. 207-219 , 2024

Link: https://doi.org/10.1111/..

4

Comparison and validation of the 2022 European LeukemiaNet ..:

Lachowiez, Curtis A. ; Long, Nicola ; Saultz, Jennifer...
Blood Advances. 7 (2023) 9 - p. 1899-1909 , 2023

Link: https://doi.org/10.1182/..

5

Immune cell proportions correlate with clinicogenomic featu..:

Romine, Kyle A. ; Bottomly, Daniel ; Yashar, William...
Frontiers in Oncology. 13 (2023) - p. , 2023

Link: https://doi.org/10.3389/..

6

Functional proteomics of patient derived head and neck squa..:

Vigoda, Myles ; Mathieson, Chase ; Evans, Nathaniel...
Cancer Biology & Therapy. 23 (2022) 1 - p. 309-317 , 2022

Link: https://doi.org/10.1080/..

7

Secondary fusion proteins as a mechanism of BCR::ABL1 kinas..:

Barnes, Evan J. ; Eide, Christopher A. ; Kaempf, Andy...
British Journal of Haematology. 200 (2022) 3 - p. 323-328 , 2022

Link: https://doi.org/10.1111/..

8

Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B..:

Thieme, Elana ; Liu, Tingting ; Bruss, Nur...
Cell Death & Disease. 13 (2022) 3 - p. , 2022

Link: https://doi.org/10.1038/..

9

Integrative analysis of drug response and clinical outcome ..:

Bottomly, Daniel ; Long, Nicola ; Schultz, Anna Reister...
Cancer Cell. 40 (2022) 8 - p. 850-864.e9 , 2022

Link: https://doi.org/10.1016/..

10

Associating drug sensitivity with differentiation status id..:

Kurtz, Stephen E. ; Eide, Christopher A. ; Kaempf, Andy...
Blood Advances. 6 (2022) 10 - p. 3062-3067 , 2022

Link: https://doi.org/10.1182/..

11

Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Op..:

Rice, William G. ; Howell, Stephen B. ; Zhang, Hongying...
Molecular Cancer Therapeutics. 21 (2022) 7 - p. 1125-1135 , 2022

Link: https://doi.org/10.1158/..

12

The AML microenvironment catalyzes a stepwise evolution to ..:

Joshi, Sunil K. ; Nechiporuk, Tamilla ; Bottomly, Daniel...
Cancer Cell. 39 (2021) 7 - p. 999-1014.e8 , 2021

Link: https://doi.org/10.1016/..

13

A noncanonical FLT3 gatekeeper mutation disrupts gilteritin..:

Joshi, Sunil K. ; Sharzehi, Setareh ; Pittsenbarger, Janét...
American Journal of Hematology. 96 (2021) 7 - p. , 2021

Link: https://doi.org/10.1002/..

14

Lentiviral-Driven Discovery of Cancer Drug Resistance Mutat..:

Yenerall, Paul ; Kollipara, Rahul K. ; Avila, Kimberley...
Cancer Research. 81 (2021) 18 - p. 4685-4695 , 2021

Link: https://doi.org/10.1158/..

15

ERBB2/HER2 mutations are transforming and therapeutically t..:

Joshi, Sunil K. ; Keck, Jamie M. ; Eide, Christopher A....
Leukemia. 34 (2020) 10 - p. 2798-2804 , 2020

Link: https://doi.org/10.1038/..